Role of pretransplant interferon-α(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers
| Autor: | O. Arslan, Gunhan Gurman, C Beyan, Meral Beksac, Harika Çelebi, A Yalcin, Deniz Sargin, Hamdi Akan, Pervin Topcuoglu, Osman Ilhan, Muhit Ozcan, Sevgi Kalayoglu-Besisik |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Transplantation Conditioning Adolescent Turkey CD34 Graft vs Host Disease Alpha interferon Gastroenterology Risk Factors Leukemia Myelogenous Chronic BCR-ABL Positive Internal medicine Living Donors Humans Transplantation Homologous Medicine Family Treatment Failure Survival rate Interferon alfa Bone Marrow Transplantation Transplantation Tumor Necrosis Factor-alpha business.industry Histocompatibility Testing Siblings Infant Hematology Middle Aged medicine.disease Survival Rate Treatment Outcome surgical procedures operative Immunology Female Stem cell business Stem Cell Transplantation Chronic myelogenous leukemia medicine.drug |
| Zdroj: | Bone Marrow Transplantation. 31:897-904 |
| ISSN: | 1476-5365 0268-3369 |
| DOI: | 10.1038/sj.bmt.1703930 |
| Popis: | Since transplantation cannot be performed immediately after the diagnosis of chronic myelogenous leukemia (CML), interferon treatment is usually required. This study aims to analyze the effects of interferon-alpha (IFN) treatment on allogeneic stem cell transplantation (SCT) outcome. A total of 106 patients aged 16-47 years and transplanted from HLA-identical sibling donors for CML in chronic phase (CP) were evaluated. In all, 48 had received IFN-alpha for a median duration of 5 months (1-18 months) until a median of 1 month prior to transplantation. Of the patients, 50 have received bone marrow transplant (BMT) whereas 56 have received peripheral blood stem cells (PBSCT) between 1991 and 1999 in three major transplant centers in Turkey. Patient characteristics in both groups were similar. More hematological responders were present in the IFN(+) patients (P=0.0001). No difference was found in engraftment kinetics. The incidences of acute or chronic graft-versus-host disease (GVHD), relapse and graft failure were similar in all patients regardless of stem cell source. Overall survival (OS) and disease-free survival (DFS) at 2 years were similar for both IFN(+) or (-) patients following SCT. With multivariate analysis, pretransplant IFN-alpha use, stem cell source, transplant year and CD34+ cell content were not found to be risk factors for OS. In conclusion, prior IFN exposure did not impair BMT or PBSCT outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|